Table 1.

Efficacy of sgp130Fc-mediated blockade of IL-6 trans-signalling in preclinical models of inflammation and cancer

Year	Disease Model	Study Outcome	Refs.
2000, 2006, 2009	Intestinal inflammation	Suppression of inflammatory bowel disease	69,182,187
2003, 2006, 2009	Rheumatoid arthritis	Improvement of established arthritis	169,188,189
2004, 2009, 2010, 2018	Colon cancer	Reduction of tumour load	182,190,191
2007, 2008	Acute local inflammation	Suppression of acute local inflammation	100,192
2011	Pancreatic cancer	Inhibition of tumour progression, reduction of ductal adenocarcinoma	164
2011, 2012	Sepsis	Up to 100% survival in sepsis models	186,193
2012	Mycobacteria infection	No increase of bacterial burden	194
2012	Atherosclerosis	Regression of atherosclerosis plaques	117
2013	Listeria infection	No increase or reduction of bacterial burden	107
2013	Pancreatitis-associated lung failure	100% survival of severe, acute experimental pancreatitis	102
2013	Lupus erythematosus	Suppression of inflammation and renal pathology	195
2015, 2016	Nephrotoxic nephritis	Amelioration of disease	196,197
2016	Lung emphysema	Improvement of disease by blockade of alveolar apoptosis	198
2016	Lung cancer	Reduction of tumour load	166
2017	Liver cancer	Reduction of tumour load	199,200
2018	Bone healing	Improvement of bone healing	103,104
2019	Abdominal aortic aneurysm	Improved survival	201
2021	Myocardial Infarction	Reduction of infarct size and preserving of cardiac function	105
2022	Perioperative neurocognitive disorder	Prevention of surgery-induced cognitive decline	202